Frazier Life Sciences
Overview
Frazier Life Sciences invests globally in private and publicly traded companies that discover, develop and commercialize innovative biopharmaceuticals. Frazier Life Sciences manages over $3.9 billion in capital, including Venture Funds focusing on company creation and private companies and the long-only Public Fund focused on small- and mid-cap public companies. Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by FLS, have completed IPOs or M&As.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Sidewinder Therapeutics | Apr 2026 | Series B | Lead |
| Sidewinder | Apr 2026 | Series B | Lead |
| Immutrin | Mar 2026 | Series A | Lead |
| Vima Therapeutics | Mar 2026 | Series A | Lead |
| AirNexis Therapeutics | Mar 2026 | Series A | Lead |
Key People
Patrick Heron
Managing Partner
Daniel Estes
General Partner
Jamie B.
General Partner And Portfolio Manager
Adam Simpson
Venture Partner
Aditya Kohli
Venture Partner
James Li
Venture Partner
Mitchell Gold
Venture Partner
Stanford Peng
Venture Partner
Tao Fu
Venture Partner
Ailsa Dalgliesh
Head Of Investor Relations
Anna H. Chen
Principal
Chris Aakre
Principal Of Company Creation
Lauren Mifflin
Principal, Company Creation
Gordon Empey
Partner General Counsel
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
